Kyntra Bio Inc (KYNB) is a biopharmaceutical company that develops drug product candidates and commercializes them through partnership and licensing agreements. Revenue is generated from drug product sales and milestone payments, primarily through collaboration agreements including the Astellas Agreements, as well as a revenue-interest financing arrangement with NovaQuest carrying $67.3 million in liability as of December 31, 2025. The company sold its China-based roxadustat operations, including FibroGen International and its 51.1% interest in Falikang, to AstraZeneca Treasury Limited in August 2025 for total consideration of $220.4 million, marking a strategic shift away from its China business. As of December 31, 2025, the company maintains ongoing clinical studies across various stages, with expenditures tied to contract research organizations and clinical study sites. The company is incorporated in Delaware.

Revenue model

Drug product revenue and milestone payments under collaboration agreements, including the Astellas Agreements. A revenue-interest financing arrangement (RIFA) with NovaQuest obligates the company to pay up to a $125.0 million cap, anticipated by 2031, against future drug product revenue and milestone receipts.

Products and services

Pharmaceutical drug product candidates in clinical development. Roxadustat, previously commercialized in China through FibroGen Beijing and the Falikang joint venture, was divested to AstraZeneca in August 2025 and is classified as a discontinued operation as of December 31, 2025.

Customers and end markets

Collaboration partners including Astellas. End markets include patients and third-party payors subject to federal and state healthcare laws. The company's products, if approved, would be marketed to physicians and healthcare providers reimbursed under Medicare, Medicaid, and other federal healthcare programs.

Value-chain role

Drug developer and licensor. Relies on contract research organizations (CROs) and clinical study sites for clinical trial execution. Commercializes through collaboration and licensing partnerships rather than direct sales at scale.

Geographic exposure

Primary operations in the United States as of December 31, 2025, following the August 2025 divestiture of China-based operations (FibroGen International, FibroGen Beijing, and the Falikang joint venture) to AstraZeneca Treasury Limited.

Source: SEC 10-K, filed 2026-03-16

Industry: Pharmaceutical Preparations Peers: CHINOOK THERAPEUTICS, INC. Arcutis Biotherapeutics Inc Avid Bioservices, Inc. Deciphera Pharmaceuticals, Inc. Gossamer Bio Inc Kymera Therapeutics Inc Rhythm Pharmaceuticals Inc Sana Biotechnology Inc Zentalis Pharmaceuticals Inc